Biopharmaceuticals
miRagen Therapeutics Secures $20 Million Series B Financing
Published in Pharma Business Week, May 7th, 2012
2012 MAY 7 -- MiRagen Therapeutics, Inc., a biopharmaceutical company developing innovative microRNA (miRNA)-based therapeutics primarily for the treatment of patients who suffer from cardiovascular and muscle disease, announced the completion of a $20 million Series B financing. The financing is being led by Remeditex Ventures, LLC, with participation from miRagen's existing investor syndicate, which includes Atlas Venture, Boulder Ventures Ltd., Amgen Ventures, and Broadview Ventures. The funding enables miRagen to advance the development of its compelling microRNA-based therapeutics pipeline.
"The Series B financing provides further validation of miRagen...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
Source: Pharma Business Week (2012-05-07)
More Articles from Pharma Business Week
- Research and Markets
Zimbabwe Pharmaceuticals and Healthcare Report Q2 2012 - Zimbabwe's Economy to Grow By 7.4% In 2012 - Pharmacokinetics
Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate - Epilepsy
Upsher-Smith Expands Epilog.us With Addition Of Expert Opinion On Epilepsy & Comorbidities - Pharmaceutical Companies
Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders - Epilepsy
Upsher-Smith Currently Recruiting People With Epilepsy To Evaluate Investigational Rescue Treatment For Seizure Clusters - Diabetes
Takeda Receives Complete Response Letter from the FDA for Type 2 Diabetes Investigational Therapies Alogliptin and Fixed-Dose Combination Alogliptin and Pioglitazone - More from this issue of Pharma Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
